New Brain-Mapping tool could prevent nerve damage during radiation
NCT ID NCT04062305
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether a non-invasive brain-mapping tool called nTMS can help doctors plan radiation treatment for brain tumors near the motor cortex—the area that controls movement. About 22 adults who already had radiation for brain tumors will undergo nTMS to see if it provides useful information to guide safer, more precise radiation dosing. The goal is to reduce the risk of nerve damage without adding extra cost or burden to patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 22 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2019
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients with brain metastases located in or near the motor cortex who have previously received SRS to that lesion within the prior 3-18 months * Patients must be able to participate in nTMS of bilateral motor cortices * Patients must be able to participate in an electromyography (EMG) * Patient's must have utilized magnetic resonance imaging (MRI) for their previous SRS treatment planning * Patient must be able to complete the Functional and Quality of Life questionnaires in English Exclusion Criteria: * Significant cognitive or psychiatric symptoms that prevent the ability to complete a physical exam, questionnaires, or participate in nTMS or EMG * Poor performance status Karnofsky performance score (KPS \< 60) that prevents the ability to participate in a physical exam, nTMS, or EMG. Patients will not be excluded if they are not able to complete the exploratory EEG analysis * Patients receiving any prior treatment that might impact their cognitive, psychiatric, or motor cortex function
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic malignant neoplasm in the brain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a memory drug and precision radiation save thinking during brain cancer treatment?
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- Brain zap study: will precision radiation save your memory?
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Radiation before brain surgery may stop cancer's return
- Smart drug targets breast cancer in the brain